GU Cancers 2021 | Predicting long-term benefit from ICIs in mUC

Srikala Sridhar, MD, FRCPC, Princess Margaret Cancer Centre, Toronto, ON, describes a retrospective, post-hoc analysis of two clinical studies (NCT01693562, NCT02261220) evaluating durvalumab, a PD-L1 inhibitor, alone or in combination with tremelimumab, a CTLA-4 inhibitor, in patients with metastatic urothelial carcinoma (mUC). The aim of this study was to identify factors that predict long-term benefit from immune checkpoint inhibitors in mUC. The analysis demonstrated that a number of characteristics, such as tumor response to treatment, were associated with long-term overall survival in this patient group. This interview took place during the 2021 Genitourinary Cancers Symposium.